(Sharecast News) - Shares in BioMarin surged on Wall Street on Friday after the pharma group agreed to buy smaller peer Amicus Therapeutics for $4.8bn, expanding its position in the rare diseases market.
Through the deal, BioMarin would get its hands on Amicus's Galafold drug for Fabry disease, and Pombiliti-Opfolda for...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE